scholarly journals A TRILOGY OF KARTEGENER SYNDROME, NSCLC WITH BRAIN METASTASIS AND SUBMASSIVE PULMONARY EMBOLISM AND MANAGEMENT WITH ASPIRATION THROMBECTOMY

CHEST Journal ◽  
2021 ◽  
Vol 160 (4) ◽  
pp. A2009-A2010
Author(s):  
vinit singh ◽  
Rana Prathap Padappayil ◽  
Ali Jaffery ◽  
DHAIRYA GOR ◽  
Patrick Lee
Keyword(s):  
Pulmonary Embolism ◽  
Brain Metastasis ◽  
Aspiration Thrombectomy ◽  
Submassive Pulmonary Embolism

Large-bore Aspiration Thrombectomy for Acute Venous Thromboembolism

2021 ◽  
Vol 39 ◽  
Author(s):  
Andy Sohn ◽  
◽  
James Hu ◽  
Jennifer Colnick ◽  
Justin George ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Pulmonary Artery ◽  
Chronic Thromboembolic Pulmonary Hypertension ◽  
Short Term ◽  
Aspiration Thrombectomy ◽  
Acute Setting ◽  
Submassive Pulmonary Embolism ◽  
Thromboembolic Pulmonary Hypertension ◽  
Acute Venous Thromboembolism

Pulmonary embolism can occur following dislodgement of deep venous thrombosis into the pulmonary artery circulation, which results in obstruction of the pulmonary artery system and can be fatal. The consequences of pulmonary embolism include hypotension, right heart strain, and hypoxia. In the long term, pulmonary embolism may lead to Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Patients who develop hypotensive massive and submassive pulmonary embolism can be treated with large-bore aspiration thrombectomy. In the acute setting, this improves short-term outcomes by decreasing the ICU stay. It can also reduce the risk of CTEPH. Options for large-bore aspiration thrombectomy include the FlowTriever™ system (Inari Medical, Irvine, CA) and the Lightning 12 vascular thrombectomy system (Penumbra Inc., Alameda, CA). This review discusses the pathophysiology of pulmonary embolism, management, and options for large-bore aspiration thrombectomy.

scholarly journals Role of Interventional Radiologist in the Management of Acute Pulmonary Embolism

2020 ◽  
Vol 37 (01) ◽  
pp. 062-073
Author(s):  
William Bremer ◽  
Charles E. Ray ◽  
Ketan Y. Shah
Keyword(s):  
Pulmonary Embolism ◽  
Interventional Radiology ◽  
Vital Role ◽  
Aspiration Thrombectomy ◽  
Catheter Directed Thrombolysis ◽  
Clinical Presentations ◽  
Submassive Pulmonary Embolism ◽  
Wide Range ◽  
Short And Long Term

AbstractPulmonary embolism is a common cause of morbidity and mortality which continues to increase in overall incidence. Because it can occur with a wide range of clinical presentations, different guidelines have been developed for appropriate risk stratification of patients; interventional radiology plays a vital role in the management of both massive and submassive pulmonary embolism. Catheter-directed therapy, including mechanical and aspiration thrombectomy, standard catheter-directed thrombolysis, and ultrasound-accelerated thrombolysis, has many benefits, including lower thrombolytic doses and intraclot administration of thrombolytic therapy. While the role of catheter-directed therapy is still being developed, four important prospective studies have demonstrated its safety and efficacy. Additional studies comparing short- and long-term clinical outcomes in patients treated with catheter-directed therapy versus anticoagulation are the next step in understanding its role within the management of submassive pulmonary embolism. Furthermore, multidisciplinary pulmonary embolism response teams, in which interventional radiology plays a crucial role, are becoming essential to appropriately managing pulmonary embolism patients, including selection of those who may benefit from catheter-directed therapy.

Aspiration Thrombectomy for Treatment of Acute Massive and Submassive Pulmonary Embolism: Initial Single-Center Prospective Experience

2018 ◽  
Vol 29 (1) ◽  
pp. 101-106 ◽  
Author(s):  
Juan José Ciampi-Dopazo ◽  
Juan María Romeu-Prieto ◽  
Marcelino Sánchez-Casado ◽  
Beatriz Romerosa ◽  
Alfonso Canabal ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Single Center ◽  
Aspiration Thrombectomy ◽  
Submassive Pulmonary Embolism

FlowTriever System for mechanical thromboembolectomy

2020 ◽  
Author(s):  
Hamid R Mojibian ◽  
Eric Chow ◽  
Jeffery Pollak
Keyword(s):  
Pulmonary Embolism ◽  
Future Research ◽  
Aspiration Thrombectomy ◽  
Research Directions ◽  
Risk Of Bleeding ◽  
Number Of Patients ◽  
Submassive Pulmonary Embolism ◽  
Thrombectomy Device ◽  
Future Research Directions ◽  
Us Fda

The systemic or catheter-directed infusion of thrombolytics benefits patients with massive and probably submassive pulmonary embolism. However, the risk of bleeding may offset benefits in a substantial number of patients. Percutaneous mechanical thromboembolectomy is an alternative to thrombolysis in those patients with contraindications to the lytic therapy, also potentially a way to avoid systemic or catheter-directed infusion of the thrombolytic all together. The Inari FlowTriever System (Inari Medical Inc, CA, USA) is the first US FDA-cleared large-bore aspiration thrombectomy device with pulmonary embolism thrombectomy indication. This article is a review of the FlowTriever System, its clinical use, current supportive literates and future research directions.

Advanced Management Options for Massive and Submassive Pulmonary Embolism

2016 ◽  
Vol 10 (1) ◽  
pp. 30 ◽  
Author(s):  
Sonika Malik ◽  
◽  
Anju Bhardwaj ◽  
Matthew Eisen ◽  
Sanjay Gandhi ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Vena Cava ◽  
Right Ventricular Dysfunction ◽  
Hemodynamic Instability ◽  
Adverse Outcomes ◽  
Intermediate Risk ◽  
Management Options ◽  
Vena Cava Filters ◽  
Submassive Pulmonary Embolism ◽  
Risk Patients

Pulmonary embolism (PE) is an important cause of morbidity and mortality and presents with significant diagnostic and therapeutic challenges. Clinical presentation ranges from mild, nonspecific symptoms to syncope, shock, and sudden death. Patients with hemodynamic instability and/ or signs of right ventricular dysfunction are at high risk for adverse outcomes and may benefit from aggressive therapy and support. Therapeutic anticoagulation is indicated in all patients in the absence of contraindications. Thrombolysis should be strongly considered in selected high- and intermediate-risk patients, either by systemic infusion or percutaneous catheter-directed therapy. Other therapeutic modalities, such as vena cava filters and surgical embolectomy, are options for patients who fail or cannot tolerate anticoagulation and/or thrombolysis. This article reviews the assessment and advanced management options for acute PE with focus on high- and intermediate-risk patients.

scholarly journals Complex space of Retzius lymphocele resulting in iliac compression and submassive pulmonary embolism after robotic Retzius sparing prostatectomy

2021 ◽  
Vol 36 ◽  
pp. 101598 ◽  
Author(s):  
Charlotte C. Goldman ◽  
Christopher P. Dall ◽  
Tamir Sholklapper ◽  
Jacob Brems ◽  
Keith Kowalczyk
Keyword(s):  
Pulmonary Embolism ◽  
Complex Space ◽  
Submassive Pulmonary Embolism

scholarly journals Clinical outcomes of submassive pulmonary embolism thrombolysis—an Indian experience

2020 ◽  
Vol 72 (1) ◽  
Author(s):  
Nadeem U. Rehman ◽  
Mohd Iqbal Dar ◽  
Manish Bansal ◽  
R. R. Kasliwal
Keyword(s):  
Pulmonary Embolism ◽  
Pulmonary Artery ◽  
Systolic Dysfunction ◽  
Massive Pulmonary Embolism ◽  
Post Treatment ◽  
Control Group ◽  
Submassive Pulmonary Embolism ◽  
Venous Thromboembolic ◽  
Pre Treatment ◽  
And Control

Abstract Background Acute pulmonary thromboembolism is the most dangerous presentation of venous thromboembolic disease. The role of thrombolysis in massive pulmonary embolism has been studied extensively, but the same is not there for submassive pulmonary embolism. This study is aimed at evaluating the effects of thrombolysis in acute submassive pulmonary embolism. This was a prospective, case-control, observational study. Patients presenting with acute submassive pulmonary embolism were divided into thrombolysis group and control group depending on whether they received thrombolysis plus anticoagulation or anticoagulation only, respectively. Results A total of 86 patients were included in the study. Forty-two patients were in the thrombolysis group, and 44 patients were in the control group. The mean ± SD age in the control and thrombolysis groups was 63.3 ± 14.7 and 56.4 ± 13.8 years, respectively. The two groups were well matched in sex distribution and associated comorbidities like COPD, active surgery, major trauma, and immobilization. On echocardiography, dilated RA/RV in pre-treatment vs. post-treatment was seen in 20 (45.5%) vs. 20 (45.5%) in the control group and 26 (61.9%) vs. 11 (26.2%) in the thrombolysis group. Similarly, RV systolic dysfunction in pre-treatment vs. post-treatment was seen in 24 (54.5%) vs. 21 (47.7%) in the control group and 22 (52.4%) vs. 8 (19.0%) in the thrombolysis group. Pulmonary artery pressure in pre-treatment vs. post-treatment was 64.4 ± 15.0 vs. 45.9 ± 9.9 mmHg in the control group and 68.3 ± 17.4 vs. 31.4 ± 6.9 mmHg in the thrombolysis group. In control vs. thrombolysis group, there were 5 vs. 1 death, 6 vs. 1 hemodynamic decompensation, and 6 vs. 1 patient needing mechanical ventilation. Conclusion Thrombolysis in submassive pulmonary embolism is associated with better right ventricular functions, lower pulmonary artery pressures, and comparable mortality rates.

Sign in / Sign up

Export Citation Format

Share Document